AT402E / Atossa Therap - LARVOL DELTA

Novel (Z)-endoxifen-related chemical entities exhibit potent anti-cancer activity in ERα+ breast cancer (AACR 2025) - "(Z)-Endoxifen (ENDX), an active metabolite of tamoxifen, is a potent, orally bioavailable selective estrogen receptor modulator with a favorable safety profile now under development for breast health applications. Its synthesis yields endoxifen-related byproducts that are new chemical entities (NCEs), including AT416E, AT416Z, AT402E and AT402Z...These findings highlight four NCEs with notable anti-cancer activity, with some matching or surpassing ENDX in several cancer-relevant cellular readouts, marking them as novel candidates for ERα+ breast cancer therapy. Further studies will advance one or more of these NCEs into in vivo models to confirm their therapeutic efficacy and potential for clinical application."

Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor